<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00193024</url>
  </required_header>
  <id_info>
    <org_study_id>SCRI BRE 39</org_study_id>
    <secondary_id>378-ONC-0030-219</secondary_id>
    <secondary_id>GIA 11168</secondary_id>
    <nct_id>NCT00193024</nct_id>
  </id_info>
  <brief_title>Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II Trial of Epirubicin/Docetaxel in the First-Line Treatment of Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SCRI Development Innovations, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aventis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharmacia and Upjohn</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SCRI Development Innovations, LLC</source>
  <brief_summary>
    <textblock>
      The epirubicin/docetaxel combination is one of the most active and best tolerated&#xD;
      taxane/anthracycline combinations. In this phase II trial, we will further evaluate the&#xD;
      feasibility, safety and effectiveness of the docetaxel/epirubicin combination, when&#xD;
      administered as first-line treatment for metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upon determination of eligibility, all patients will receive:&#xD;
&#xD;
      Docetaxel + Epirubicin&#xD;
&#xD;
      Both drugs will be repeated at 21-day intervals&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>September 2001</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <primary_completion_date type="Actual">October 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response rate of the docetaxel/epirubicin combination in the first-line treatment of patients with metastatic breast cancer</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of the docetaxel/epirubicin combination in the first-line treatment of patients with metastatic breast cancer</measure>
  </secondary_outcome>
  <enrollment>90</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be included in this study, you must meet the following criteria:&#xD;
&#xD;
          -  Metastatic breast cancer confirmed by biopsy.&#xD;
&#xD;
          -  Received no previous chemotherapy for metastatic breast cancer.&#xD;
&#xD;
          -  Prior hormonal therapy is acceptable.&#xD;
&#xD;
          -  Measurable or evaluable disease.&#xD;
&#xD;
          -  Able to perform activities of daily living without considerable assistance&#xD;
&#xD;
          -  Adequate bone marrow, liver and kidney function&#xD;
&#xD;
          -  Must be able to understand the nature of this study and give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        You cannot participate in this study if any of the following apply to you:&#xD;
&#xD;
          -  Age &lt; 18 years.&#xD;
&#xD;
          -  Cardiac ejection fraction &lt; 45%.&#xD;
&#xD;
          -  Women who are pregnant or lactating.&#xD;
&#xD;
          -  Patients with meningeal metastases are ineligible.&#xD;
&#xD;
          -  Moderate peripheral neuropathy&#xD;
&#xD;
          -  History of hypersensitivity reaction to Taxotere&#xD;
&#xD;
          -  Males with metastatic breast cancer&#xD;
&#xD;
        Please note: There are additional inclusion/exclusion criteria. The study center will&#xD;
        determine if you meet all of the criteria. If you do not qualify for the trial, study&#xD;
        personnel will explain the reasons. If you do qualify, study personnel will explain the&#xD;
        trial in detail and answer any questions you may have.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John D. Hainsworth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <link>
    <url>http://informahealthcare.com/doi/abs/10.1080/07357900600814060</url>
    <description>Published article in Cancer Investigation</description>
  </link>
  <results_reference>
    <citation>Hainsworth JD, Yardley DA, Spigel DR, Meluch AA, Rinaldi D, Schnell FM, Greco FA. Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial. Cancer Invest. 2006 Aug-Sep;24(5):469-73.</citation>
    <PMID>16939953</PMID>
  </results_reference>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>May 2, 2011</last_update_submitted>
  <last_update_submitted_qc>May 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2011</last_update_posted>
  <responsible_party>
    <name_title>SCRI Oncology Research Consortium</name_title>
    <organization>SCRI</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

